Bioceres Crop Solutions Corp. (BIOX)
- Previous Close
11.51 - Open
11.61 - Bid 11.50 x 100
- Ask 11.58 x 200
- Day's Range
11.47 - 11.62 - 52 Week Range
10.10 - 14.20 - Volume
40,636 - Avg. Volume
51,984 - Market Cap (intraday)
697.161M - Beta (5Y Monthly) --
- PE Ratio (TTM)
32.89 - EPS (TTM)
0.35 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.25
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Bolivia, Brazil, Colombia, Estonia, the United States, Paraguay, Russia, South Africa, France, Uruguay, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.
biocerescrops.comRecent News: BIOX
Performance Overview: BIOX
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOX
Valuation Measures
Market Cap
697.16M
Enterprise Value
934.96M
Trailing P/E
32.88
Forward P/E
14.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
2.22
Enterprise Value/Revenue
2.06
Enterprise Value/EBITDA
14.43
Financial Highlights
Profitability and Income Statement
Profit Margin
0.70%
Return on Assets (ttm)
2.68%
Return on Equity (ttm)
1.63%
Revenue (ttm)
445.55M
Net Income Avi to Common (ttm)
3.11M
Diluted EPS (ttm)
0.35
Balance Sheet and Cash Flow
Total Cash (mrq)
16.4M
Total Debt/Equity (mrq)
77.65%
Levered Free Cash Flow (ttm)
--
Research Analysis: BIOX
Company Insights: BIOX
BIOX does not have Company Insights